Henderson Jeffrey William's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Mar 3, 2025
- Accession no.
- 0001415889-25-006323
- Filed
- Mar 3, 2025
- Trade date
- Mar 3, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $293.5K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henderson Jeffrey WilliamCIK 0001324015 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | Common Stock | SSaleDisposed | −1,795 | $57.93 | −$103,984.35 | 36,816 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −3,205 | $59.12 | −$189,479.6 | 33,611 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.